Comment on: “Descemet Membrane Endothelial Keratoplasty After Failed Penetrating Keratoplasty”

No abstract available
Source: Cornea - Category: Opthalmology Tags: Letters to the Editor Source Type: research

Related Links:

Conclusions: Although there are significantly fewer amounts of peripheral cells available after graft preparation for keratoplasty, these cells can still be used for endothelial cell culture due to their proliferative capability. The peripheral cells that are discarded after graft preparation can thus be utilized to increase the donor endothelial cell pool for regenerative treatments. PMID: 31428467 [PubMed]
Source: Journal of Ophthalmology - Category: Opthalmology Tags: J Ophthalmol Source Type: research
We read with great interest the article “Effect of keratoconus severity on clinical outcomes after deep anterior lamellar keratoplasty” by Feizi and associates.1 The authors have brought out clarity on an essential aspect of keratoplasty in keratoconus, that is, the impact of clinical severity on the outcomes of deep anterior lamellar keratoplasty (DALK). However, there are a few concerns that we would like to highlight.
Source: American Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Correspondence Source Type: research
Whether complement dysregulation directly contributes to the pathogenesis of peripheral nervous system diseases, including sensory neuropathies, is unclear. We addressed this important question in a mouse model of ocular HSV-1 infection, where sensory nerve damage is a common clinical problem. Through genetic and pharmacologic targeting, we uncovered a central role for C3 in sensory nerve damage at the morphological and functional levels. Interestingly, CD4 T cells were central in facilitating this complement-mediated damage. This same C3/CD4 T cell axis triggered corneal sensory nerve damage in a mouse model of ocular gra...
Source: eLife - Category: Biomedical Science Tags: Immunology and Inflammation Microbiology and Infectious Disease Source Type: research
Conditions:   Fuchs' Endothelial Dystrophy;   Cataract Intervention:   Drug: Netarsudil 0.02% Ophthalmic Solution Sponsor:   Massachusetts Eye and Ear Infirmary Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Fungal Keratitis Intervention:   Device: Lamellar keratoplasty-ABCcolla® Collagen Ophthalmic Matrix Sponsor:   ACRO Biomedical Co. Ltd Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Corneal Transplant | Opthalmology